Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Belapectin

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR-MD-02

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2021

            Details:

            Company will present poster titled "An innovative clinical development program: belapectin for NASH cirrhosis". Belapectin is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer, Gal-3 inhibitor for esophageal varices in patients with NASH cirrhosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Belapectin

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR-MD-02

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2020

            Details:

            Compelling NASH-RX trial result could potentially lead to accelerated FDA approval and/or partnership opportunities and fulfill an acute unmet medical need.